Subcutaneous apomorphine in Parkinson's disease.
作者信息
Chaudhuri K R, Clough C
出版信息
BMJ. 1998 Feb 28;316(7132):641. doi: 10.1136/bmj.316.7132.641.
Abstract
摘要
相似文献
1
Subcutaneous apomorphine in Parkinson's disease.帕金森病中的皮下注射阿扑吗啡
BMJ. 1998 Feb 28;316(7132):641. doi: 10.1136/bmj.316.7132.641.
2
Future delivery systems for apomorphine in patients with Parkinson's disease.帕金森病患者阿扑吗啡的未来给药系统。
Adv Neurol. 1999;80:535-44.
3
Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson's disease.
Mov Disord. 2006 May;21(5):727-8. doi: 10.1002/mds.20852.
4
Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.皮下注射阿扑吗啡：关于其在帕金森病中应用的循证综述
Drugs Aging. 2004;21(11):687-709. doi: 10.2165/00002512-200421110-00001.
5
Role of apomorphine in the treatment of Parkinson's disease.阿扑吗啡在帕金森病治疗中的作用。
CNS Drugs. 2015 Feb;29(2):83-9. doi: 10.1007/s40263-014-0221-z.
6
Sublingual apomorphine (Kynmobi) for Parkinson's disease.用于帕金森病的舌下含服阿扑吗啡（Kynmobi）。
Med Lett Drugs Ther. 2020 Oct 19;62(1609):165-166.
7
Apomorphine-subcutaneous--Bertek/Britannia.阿扑吗啡皮下注射剂——伯特克/大不列颠制药公司。
Drugs R D. 2004;5(4):211-2. doi: 10.2165/00126839-200405040-00004.
8
Acute lethargy after abrupt apomorphine withdrawal in Parkinson's disease.帕金森病患者突然停用阿扑吗啡后出现急性嗜睡。
J Neurol Sci. 2019 Sep 15;404:44-46. doi: 10.1016/j.jns.2019.07.011. Epub 2019 Jul 10.
9
My husband's journey with Parkinson's disease.我丈夫与帕金森病的抗争历程。
RN. 2008 Oct;71(10):27-8.
10
Apomorphine-induced penile erections in Parkinson's disease.阿扑吗啡诱发帕金森病患者阴茎勃起
Mov Disord. 1998 May;13(3):536-9. doi: 10.1002/mds.870130326.
引用本文的文献
1
L-DOPA-therapy in Parkinson's disease: some personal reflections on L-DOPA therapy from Vienna and Berlin.左旋多巴治疗帕金森病：来自维也纳和柏林的关于左旋多巴治疗的一些个人思考。
J Neural Transm (Vienna). 2023 Nov;130(11):1323-1335. doi: 10.1007/s00702-023-02692-9. Epub 2023 Oct 5.
2
Evaluation of the Association Between Serum Levels of Testosterone and Prolactin With 6- Hydroxydopamine-Induced Parkinsonism in Male Rats.雄性大鼠血清睾酮和催乳素水平与6-羟基多巴胺诱导的帕金森病之间的关联评估
Basic Clin Neurosci. 2021 Jul-Aug;12(4):453-464. doi: 10.32598/bcn.2021.671.3. Epub 2021 Jul 1.
3
Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors.研究依布硒啉、白屈菜红碱和阿扑吗啡对谷氨酰胺酶的抑制作用及其动力学特征。
Biochem Biophys Res Commun. 2013 Aug 23;438(2):243-8. doi: 10.1016/j.bbrc.2013.06.110. Epub 2013 Jul 10.
4
Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?阿扑吗啡与精神分裂症的多巴胺假说：一个困境？
J Psychiatry Neurosci. 2001 May;26(3):203-20.
5
Extra cost of subcutaneous apomorphine would pay for personal nurses.皮下注射阿扑吗啡的额外费用将支付私人护士的费用。
BMJ. 1998 Aug 29;317(7158):602. doi: 10.1136/bmj.317.7158.602a.
本文引用的文献
1
Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment.阿扑吗啡在帕金森病患者口服治疗出现神经精神并发症时的应用。
Parkinsonism Relat Disord. 1997 Apr;3(2):103-7. doi: 10.1016/s1353-8020(97)00009-6.
2
Apomorphine in Parkinson's disease.阿扑吗啡在帕金森病中的应用。
Trans Am Neurol Assoc. 1951;56:251-3.
3
Clinical usefulness of apomorphine in movement disorders.阿扑吗啡在运动障碍中的临床应用价值。
Clin Neuropharmacol. 1994 Jun;17(3):243-59. doi: 10.1097/00002826-199406000-00004.
4
Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.皮下注射阿扑吗啡治疗帕金森病：长达五年的长期给药反应
Mov Disord. 1993 Apr;8(2):165-70. doi: 10.1002/mds.870080208.
5
The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys.多巴胺 D1 激动剂 SKF 81297 与多巴胺 D2 激动剂 LY 171555 协同作用，刺激 1-甲基-4-苯基-1,2,3,6-四氢吡啶损伤的帕金森病恒河猴的运动行为。
Mov Disord. 1994 Nov;9(6):664-72. doi: 10.1002/mds.870090613.
6
On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study.帕金森病的开关波动。一项临床与神经药理学研究。
Brain. 1984 Jun;107 ( Pt 2):487-506. doi: 10.1093/brain/107.2.487.
7
Similarities between neurologic effects of L-dopa and of apomorphine.左旋多巴与阿扑吗啡对神经系统作用的相似性。
N Engl J Med. 1970 Jan 1;282(1):31-3. doi: 10.1056/NEJM197001012820107.
8
Subcutaneous apomorphine in parkinsonian on-off oscillations.皮下注射阿扑吗啡治疗帕金森病的开关现象
Lancet. 1988 Feb 20;1(8582):403-6. doi: 10.1016/s0140-6736(88)91193-2.
9
Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease.阿扑吗啡联合脑外多巴胺受体抑制剂治疗帕金森病的疗效
Lancet. 1979 May 5;1(8123):954-6. doi: 10.1016/s0140-6736(79)91725-2.
Zotero 插件